A Phase I Study of Oral Sapacitabine and Oral Seliciclib in Patients With Advanced Solid Tumors

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 28 Dec 2021

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Sapacitabine (Primary) ; Seliciclib (Primary)
Indications Advanced breast cancer; Ovarian cancer; Pancreatic cancer; Solid tumours
Focus Adverse reactions
Sponsors Cyclacel Pharmaceuticals

07 Dec 2021 Status changed from recruiting to completed.
03 Apr 2019 Results (n=20) from an expansion cohort assessing the safety and efficacy of oral sapacitabine and oral seliciclib regimen in patients with metastatic breast cancer and BRCA1/2 mutations presented at the 110th Annual Meeting of the American Association for Cancer Research
05 Mar 2019 According to a Cyclacel Pharmaceuticals media release, data from expansion cohort of the study in patients with metastatic breast cancer and BRCA1/2 mutations, will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2019.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com